Citations

Clear

6273 citation(s) found for "To, Andrew".

Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the
Kharfan‐Dabaja, Mohamed A. , Ayala, Ernesto , Blaise, Didier , Itälä‐Remes, Maija , Forcade, Édouard , Rabitsch, Werner , Bulabois, Claude‐Eric , Grillo, Giovanni , Rambaldi, Alessandro , Fanin, Renato , Zallio, Francesco, Renzo, Nicola Di , Novis, Yana , McDonald, Andrew , Herrera, Concha , Nagler, Arnon , Ciceri, Fabio , Blaise, Didier , Rambaldi, Alessandro , Labopin, Myriam , Bazarbachi, Ali , Vydra, Jan , Bramanti, Stéfania , Schmid, Christoph , Busca, Alessandro , Zecca, Marco , Kröger, Nicolaus , Koç, Yener , Sanz, Jaime , Mohty, Mohamad

Mayo Clinic

HemaSphere | June 27, 2023 | Volume: 7 | Issue: 7 | Pages: e920

10.1097/hs9.0000000000000920 | PMID 37388926 Get It

Availability of haploidentical donors has broadened utilization of allogeneic hematopoietic cell transplantation (allo-HCT). Peripheral blood stem cells (PBSC) are being used with increased frequency in haploidentical allo-HCT. We evaluated extent of HLA disparity (2–3/8 versus 4/8 HLA antigen mismatches) on post-allograft outcomes when using T-cell replete PBSC from haploidentical donors for acute myeloid leukemia in first complete remission. Primary objectives entailed assessing cumulative incidence of grade 2–4 acute graft-versus-host disease (GVHD) and chronic GVHD (any grade). A total of 645 patients received a haploidentical allo-HCT from a donor with either 2–3 of 8 HLA antigen mismatches (n = 180) or with 4 of 8 HLA antigen mismatches (n = 465). Presence of 2–3 of 8 versus 4 of 8 HLA mismatches did not affect the incidence of acute GVHD (grade 2–4) and chronic GVHD (any grade). Overall survival (OS), leukemia-free survival (LFS) relapse incidence (RI), nonrelapse mortality and the composite endpoint of GVHD-free relapse-free survival were also similar among the groups. Pertaining to HLA-B leader matching effect, our analysis did not discern any difference in aforementioned post-allograft outcomes for this variable. However, in univariate analysis, absence of an antigen mismatch in HLA-DPB1 showed a trend for better OS. Notwithstanding inherent limitations associated with registry data, our results did not show an advantage of selecting a haploidentical donor with 2–3 of 8 HLA antigen mismatches over one with 4 of 8 HLA antigen mismatches when using PBSC as the cell source. Adverse cytogenetics remains a major adverse determinant of inferior OS and LFS and a higher RI. Using reduced-intensity conditioning yielded worse OS and LFS.
Seizure characteristics and outcomes in patients with neurological conditions related to high‐risk paraneoplastic antibodies
Smith, Kelsey M. , Gupta, Pranjal , Ζεκερίδου, Αναστασία , López‐Chiriboga, A. Sebastian , Sánchez, Cristina Valencia, Pittock, Sean J. , Dubey, Divyanshu , Gupta, Pranjal , Pittock, S J , Thakolwiboon, Smathorn , Chia, Nicholas H , Lopez Chiriboga, Alfonso S, Valencia Sanchez, Cristina, Dubey, Divyanshu , Smith, Kelsey M , Britton, Jeffrey W. , Chia, Nicholas , Flanagan, Eoin P. , McKeon, Andrew , Gupta, Pranjal

Mayo Clinic

Epilepsia | June 27, 2023 | Volume: 64 | Issue: 9 | Pages: 2385-2398

10.1111/epi.17695 | PMID 37366270 Get It

AbstractObjectiveSeizures are a common manifestation of paraneoplastic neurologic syndromes. The objective of this study was to describe the seizure characteristics and outcomes in patients with high‐risk paraneoplastic autoantibodies (>70% cancer association) and to determine factors associated with ongoing seizures.MethodsPatients from 2000 to 2020 with seizures and high‐risk paraneoplastic autoantibodies were retrospectively identified. Factors associated with ongoing seizures at last follow‐up were evaluated.ResultsSixty patients were identified (34 males, median age at presentation = 52 years). ANNA1‐IgG (Hu; n = 24, 39%), Ma2‐IgG (n = 14, 23%), and CRMP5‐IgG (CV2; n = 11, 18%) were the most common underlying antibodies. Seizures were the initial presenting symptom in 26 (43%), and malignancy was present in 38 (63%). Seizures persisted for >1 month in 83%, and 60% had ongoing seizures, with almost all patients (55/60, 92%) still being on antiseizure medications at last follow‐up a median of 25 months after seizure onset. Ongoing seizures at last follow‐up were associated with Ma2‐IgG or ANNA1‐IgG compared to other antibodies (p = .04), highest seizure frequency being at least daily (p = .0002), seizures on electroencephalogram (EEG; p = .03), and imaging evidence of limbic encephalitis (LE; p = .03). Death occurred in 48% throughout the course of follow‐up, with a higher mortality in patients with LE than in those without LE (p = .04). Of 31 surviving patients at last follow‐up, 55% continued to have intermittent seizures.SignificanceSeizures in the setting of high‐risk paraneoplastic antibodies are frequently resistant to treatment. Ongoing seizures are associated with ANNA1‐IgG and Ma2‐IgG, high seizure frequency, and EEG and imaging abnormalities. Although a subset of patients may respond to immunotherapy and achieve seizure freedom, poor outcomes are frequently encountered. Death was more common among patients with LE.
Tubularization of the gastric pouch helps sustain weight loss after transoral outlet reduction for post-Roux-en-Y gastric bypass weight recurrence
Abboud, Donna Maria , Ghazi, Rabih , Brunaldi, Vitor , Gala, Khushboo , Baroud, Serge , Kerbage, Anthony , Abdul-Razzak, Farah, Annan, Karim Al , Rapaka, Babusai , Yao, Rebecca , AbdulRazzak, Farah, Al Annan, Karim, Vargas, Eric J , Storm, Andrew C , Abboud, Donna M , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | June 26, 2023 | Volume: 11 | Issue: 09 | Pages: E829-E834

10.1055/a-2117-8113 | PMID 37719801 Get It

Abstract Background and study aims Traditional transoral outlet reduction (TORe) is a minimally invasive endoscopic approach focused on reducing the aperture of the gastrojejunal (GJ) anastomosis, while the tubular transoral outlet reduction (tTORe) consists of tabularization of the distal pouch utilizing an O-shape gastroplasty suturing pattern. The primary aim of this study was to compare short-term weight loss between TORe and tTORe. Patients and methods Retrospective analysis of a prospectively maintained database was conducted at a tertiary care bariatric center of excellence. The study included patients with history of Roux-en-Y gastric bypass (RYGB) who had an endoscopic revision by TORe or tTORe and had follow-up data in their electronic medical record. The primary outcome was percent total body weight loss (%TBWL). Results A total of 128 patients were included (tTORe=85, TORe=43). At 3 and 6 months, the tTORe and TORe cohorts presented similar %TBWL (3 months: 8.5±4.9 vs. 7.3±6.0, P = 0.27 and 6 months: 8.1±7.4 vs. 6.8±5.6, P = 0.44). At 9 months, there was a trend toward greater weight loss in the tTORe cohort (9.7±8.6% vs. 5.1±6.8%, P = 0.053). At 12 months, the %TBWL was significantly higher in the tubularization group compared to the standard group (8.2±10.8 vs. 2.3±7.3%, P = 0.01). Procedure time was significantly different between both groups (60.5 vs. 53.4 minutes, P = 0.03). The adverse events rate was similar between groups (8.2% vs. 7.0% for tTORe and TORe, respectively, P = 0.61). Conclusions The tTORe enhances efficacy and durability of the standard procedure without adding significant procedure-related risks.
Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure
Alkhatry, Maryam, Rapaka, Babusai , Maselli, Daniel B. , Abboud, Donna Maria , Brunaldi, Vitor , Mahmoud, Tala , Ghazi, Rabih , Razzak, Farah Abdul, Gala, Khushboo, Joudah, Imad, Housen, Fedaa, Qadi, Sana Al, Brunaldi, Vitor Ottoboni , Abdul Razzak, Farah, Vargas, Eric J , Storm, Andrew C , Abboud, Donna M , Gala, Khushboo , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy | June 26, 2023 | Volume: 55 | Issue: 11 | Pages: 1028-1034

10.1055/a-2117-6274 | PMID 37364600 Get It

Background The primary obesity surgery endoluminal 2.0 (POSE 2.0) procedure involves full-thickness gastric body plications to narrow the stomach using durable suture anchor pairs. We evaluated POSE 2.0 as a treatment strategy for nonalcoholic fatty liver disease (NAFLD) in patients with obesity. Methods Adults with obesity and NAFLD were prospectively allocated based on their preference to undergo POSE 2.0 with lifestyle modification or lifestyle modification alone (control). Primary end points were improvement in controlled attenuation parameter (CAP) and resolution of hepatic steatosis at 12 months. Secondary end points included %total body weight loss (%TBWL), change in serum measures of hepatic steatosis and insulin resistance, and procedure safety. Results 42 adult patients were included (20 in the POSE 2.0 arm and 22 in the control arm). At 12 months, POSE 2.0 significantly improved CAP, whereas lifestyle modification alone did not (P < 0.001 for POSE 2.0; P = 0.24 for control). Similarly, both resolution of steatosis and %TBWL were significantly higher with POSE 2.0 than with control at 12 months. Compared with controls, POSE 2.0 significantly improved liver enzymes, hepatic steatosis index, and aspartate aminotransferase to platelet ratio at 12 months. There were no serious adverse events. Conclusion POSE 2.0 was effective for NAFLD in patients with obesity, with good durability and safety profile.
Using DEPendency of Association on the Number of Top Hits (DEPTH) as a Complementary Tool to Identify Novel Colorectal Cancer Susceptibility Loci
Lai, John , Wong, Chi Kuen , Schmidt, Daniel F. , Kapuscinski, Miroslaw K. , Alpen, Karen , MacInnis, Robert J. , Buchanan, Daniel D. , Win, Aung Ko , Figueiredo, Jane C. , Chan, Andrew T. , Harrison, Tabitha A. , Hoffmeister, Michael , White, Emily , Pai, Rish K. , Peters, Ulrike , Win, Aung K , Marchand, Loïc Le , Pai, R K , Peters, Ulrike , Hopper, John L. , Jenkins, Mark A , Makalic, Enes , Buchanan, Daniel D , Hoffmeister, Michael , Harrison, Tabitha A , Maclnnis, Robert , Chan, Andrew T , Marchand, Loı̈c Le , Hopper, John L. , Jenkins, Mark A. , Makalic, Enes

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 26, 2023 | Volume: 32 | Issue: 9 | Pages: 1153-1159

10.1158/1055-9965.epi-22-1209 | PMID 37364297 Get It

Abstract Background: DEPendency of association on the number of Top Hits (DEPTH) is an approach to identify candidate susceptibility regions by considering the risk signals from overlapping groups of sequential variants across the genome. Methods: We applied a DEPTH analysis using a sliding window of 200 SNPs to colorectal cancer data from the Colon Cancer Family Registry (CCFR; 5,735 cases and 3,688 controls), and Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO; 8,865 cases and 10,285 controls) studies. A DEPTH score &gt; 1 was used to identify candidate susceptibility regions common to both analyses. We compared DEPTH results against those from conventional genome-wide association study (GWAS) analyses of these two studies as well as against 132 published susceptibility regions. Results: Initial DEPTH analysis revealed 2,622 (CCFR) and 3,686 (GECCO) candidate susceptibility regions, of which 569 were common to both studies. Bootstrapping revealed 40 and 49 candidate susceptibility regions in the CCFR and GECCO data sets, respectively. Notably, DEPTH identified at least 82 regions that would not be detected using conventional GWAS methods, nor had they been identified by previous colorectal cancer GWASs. We found four reproducible candidate susceptibility regions (2q22.2, 2q33.1, 6p21.32, 13q14.3). The highest DEPTH scores were in the human leukocyte antigen locus at 6p21 where the strongest associated SNPs were rs762216297, rs149490268, rs114741460, and rs199707618 for the CCFR data, and rs9270761 for the GECCO data. Conclusions: DEPTH can identify candidate susceptibility regions for colorectal cancer not identified using conventional analyses of larger datasets. Impact: DEPTH has potential as a powerful complementary tool to conventional GWAS analyses for discovering susceptibility regions within the genome.
Emergence of Inducible Macrolide Resistance in Mycobacterium chelonae Due to Broad-Host-Range Plasmid and Chromosomal Variants of the Novel 23S rRNA Methylase Gene, erm (55)
Brown‐Elliott, Barbara A. , Wallace, Richard J. , Wengenack, Nancy L. , Workman, Sean D. , Cameron, Andrew D. S. , Bush, Georgie, Hughes, M. Dolores, Melton, Stephanie, Gonzalez-Ramirez, Bibiana, Rodrı́guez, Eliana , Somayaji, Kavya, Klapperich, Courtney, Viers, Mary, Bolaji, Ayooluwa , Rempel, Emma , Alexander, David C. , Rodriguez, Eliana, Rempel, Emma

Mayo Clinic

Journal of Clinical Microbiology | June 23, 2023 | Volume: 61 | Issue: 7 | Pages: No page available

10.1128/jcm.00428-23 | PMID 37347171 Get It

Macrolides are a mainstay of therapy for infections due to nontuberculous mycobacteria (NTM). Among rapidly growing mycobacteria (RGM), inducible macrolide resistance is associated with four chromosomal 23S rRNA methylase ( erm ) genes.
The Reviewer Academy of the Society of Critical Care Medicine: Key Principles and Strategic Plan
Aslakson, Rebecca A. , Frazee, Erin N. , Meissen, Heather , Morrow, Brenda M., Nazer, Lama , Branson, Richard D. , Mayer, Kirby P. , Napolitano, Natalie , Lane‐Fall, Meghan B. , John, Preeti R. , Dellinger, R. Phillip, Parker, Margaret M. , Argent, Andrew C. , Boateng, Adjoa , Green, Thomas P. , Kudchadkar, Sapna R. , Checchia, Paul A. , Alexander, Peta , Lee, Jan Hau , Morrow, Brenda May , Sikora, Andrea , Maslove, David M. , Rech, Megan A. , Sorce, Lauren R. , Tasker, Robert C. , Buchman, Timothy G.

Mayo Clinic

Critical Care Medicine | June 21, 2023 | Volume: 51 | Issue: 9 | Pages: 1111-1123

10.1097/ccm.0000000000005962 | PMID 37341529 Get It

The Society of Critical Care Medicine (SCCM) Reviewer Academy seeks to train and establish a community of trusted, reliable, and skilled peer reviewers with diverse backgrounds and interests to promote high-quality reviews for each of the SCCM journals. Goals of the Academy include building accessible resources to highlight qualities of excellent manuscript reviews; educating and mentoring a diverse group of healthcare professionals; and establishing and upholding standards for insightful and informative reviews. This manuscript will map the mission of the Reviewer Academy with a succinct summary of the importance of peer review, process of reviewing a manuscript, and the expected ethical standards of reviewers. We will equip readers to target concise, thoughtful feedback as peer reviewers, advance their understanding of the editorial process and inspire readers to integrate medical journalism into diverse professional careers.
Reperfusion Delays and Outcomes Among Patients With ST-Segment–Elevation Myocardial Infarction With and Without Cardiogenic Shock
Kochan, Andrew , Lee, Terry , Moghaddam, Nima , Milley, Grace, Singer, Joel , Cairns, John A. , Wong, Graham C., Jentzer, Jacob C. , Diepen, Sean van , Alviar, Carlos L. , van Diepen, Sean , Fordyce, Christopher B , Jentzer, Jacob C , Milley, Grace, Fordyce, Christopher B.

Mayo Clinic

Circulation: Cardiovascular Interventions | June 20, 2023 | Volume: 16 | Issue: 6 | Pages: No page available

10.1161/circinterventions.122.012810 | PMID 37339233 Get It

Background: Mortality remains high in patients with ST-segment–elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS), and early reperfusion has been shown to improve outcomes. We analyzed the association between first medical contact (FMC)-to-percutaneous coronary angiography time with mortality and major adverse cardiovascular events among patients with STEMI with and without CS. Methods: We performed a retrospective analysis of the Vancouver Coastal Health Authority STEMI registry, including all patients with STEMI who received primary percutaneous coronary angiography between January 1, 2010, and December 31, 2020, and stratified them by presence or absence of CS at hospital arrival. The primary outcome was in-hospital mortality, the secondary outcome was in-hospital major adverse cardiovascular events, defined as a composite of the first occurrence of mortality, cardiac arrest, heart failure, intracerebral hemorrhage, cerebrovascular accident, or reinfarction. Mixed effects logistic regression with restricted cubic splines was used to estimate the relationships between FMC-to-device time and the outcomes in the CS and non-CS groups. Results: 2929 patients were included, 9.4% (n=275) had CS. Median FMC-to-device time was 113.5 (interquartile range, 93.0–145.0) and 103.0 (interquartile range, 85.0–130.0) minutes for patients with CS and without CS, respectively. More patients with CS had FMC-to-device times above guideline recommendations (76.6% versus 54.1%, P <0.001). Between 60 and 90 minutes, for each 10-minute increase in FMC-to-device time, absolute mortality for patients with CS increased by 4% to 7%, whereas for patients without CS, it increased by <0.5%. Conclusions: Among patients with STEMI undergoing primary percutaneous coronary angiography, reperfusion delays among patients with CS are associated with significantly worse outcomes. Strategies to reduce FMC-to-device times for patients with STEMI presenting with CS are required.
Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium
Mehran, Roxana , Krucoff, Mitchell W., Baber, Usman , Bhatt, Deepak L. , Collet, Jean‐Philippe, Cuisset, Thomas, Luca, Leonardo De , Farb, Andrew , Hong, Myeong‐Ki , Kimura, Takeshi , Magee, Adrian, Matsumura, Ryosuke, Mochizuki, Shuichi , Pereira, Naveen L. , Rollini, Fabiana , Shirai, Yuko, Sibbing, Dirk , Smits, Peter C., Storey, Robert F. , Windecker, Stephan , Yeh, Robert W. , Morice, Marie‐Claude, Capodanno, Davide , Mehran, Roxana , Bhatt, Deepak L , De Luca, Giuseppe , De Luca, Leonardo , Hahn, Joo‐Yong , Hong, Myeong-Ki , James, Stefan Karl , Kastrati, Adnan , Kimura, Takeshi , Lemos, Pedro A , Lopes, Renato D , Mochizuki, Shuichi , O'Donoghue, Michelle L , Pereira, Naveen L , Rao, Sunil V , Smits, Peter C , Steg, P Gabriel , Storey, Robert F , Ten Berg, Jurrien , Valgimigli, Marco , Vranckx, Pascal , Watanabe, Hirotoshi , Windecker, Stephan , Serruys, Patrick W , Yeh, Robert W , Angiolillo, Dominick J , Capranzano, Piera , Collet, Jean‐Philippe , Cuisset, Thomas , Franchi, Francesco , Gibson, C. Michael , Lópes, Renato D. , Matsumura, Ryosuke, Rao, Sunil V. , Shirai, Yuko, Sibbing, Dirk , Steg, Philippe Gabríel , Valgimigli, Marco , Serruys, Patrick W. , Angiolillo, Dominick J.

Mayo Clinic

Circulation | June 19, 2023 | Volume: 147 | Issue: 25 | Pages: 1933-1944

10.1161/circulationaha.123.064473 | PMID 37335828 Get It

Antiplatelet therapy is the mainstay of pharmacologic treatment to prevent thrombotic or ischemic events in patients with coronary artery disease treated with percutaneous coronary intervention and those treated medically for an acute coronary syndrome. The use of antiplatelet therapy comes at the expense of an increased risk of bleeding complications. Defining the optimal intensity of platelet inhibition according to the clinical presentation of atherosclerotic cardiovascular disease and individual patient factors is a clinical challenge. Modulation of antiplatelet therapy is a medical action that is frequently performed to balance the risk of thrombotic or ischemic events and the risk of bleeding. This aim may be achieved by reducing (ie, de-escalation) or increasing (ie, escalation) the intensity of platelet inhibition by changing the type, dose, or number of antiplatelet drugs. Because de-escalation or escalation can be achieved in different ways, with a number of emerging approaches, confusion arises with terminologies that are often used interchangeably. To address this issue, this Academic Research Consortium collaboration provides an overview and definitions of different strategies of antiplatelet therapy modulation for patients with coronary artery disease, including but not limited to those undergoing percutaneous coronary intervention, and consensus statements on standardized definitions.
Environmentally Sustainable Radiation Oncology: Can We Turn the Tides?
Anderson, Justin D. , McComas, Kyra N. , Tam, Andrew , Bloom, Julie R. , Lichter, Katie E.

Mayo Clinic

Applied Radiation Oncology | June 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: 46-47

10.37549/aro1320 Get It